A viral 'loose cannon' enzyme helps phages shut down bacterial defenses

Antimicrobial resistance is rising worldwide, prompting the scientific community to seek alternative treatments that can outpace evolving bacterial defenses. Among the most promising options are bacteriophages—viruses that specifically infect and destroy bacteria. By targeting only pathogenic species, phages can eradicate infections without disturbing the beneficial microbiota, offering a potential solution for strains that have become resistant to conventional antibiotics.

Research into phage therapy is accelerating as laboratories demonstrate its efficacy against a range of drug‑resistant bacteria, including methicillin‑resistant *Staphylococcus aureus* and carbapenem‑resistant *Enterobacteriaceae*. Clinical trials are now underway in several countries, evaluating safety, dosing, and delivery methods such as topical sprays and intravenous infusions. Early results suggest that phages can clear infections that remain stubbornly persistent after standard treatment, and that they can be combined with antibiotics to enhance bacterial killing.

If these trials continue to show positive outcomes, phage therapy could become a vital tool in the global fight against antimicrobial resistance. Regulatory pathways are being established to streamline approval processes, and partnerships between academia and industry are growing to support large‑scale production. The emergence of phage-based treatments marks a significant shift toward precision medicine in infectious disease, potentially restoring the effectiveness of bacterial infections that have outlived traditional drugs.